Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
Silo Pharma (NASDAQ: SILO) has filed a provisional patent application with the USPTO for its lead asset SPC-15, targeting treatments for stress-induced psychiatric disorders, including PTSD. The patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
This filing enhances Silo's intellectual property portfolio for SPC-15 technology, which was originally licensed through a collaboration with Columbia University. The exclusive agreement grants Silo global rights to develop, manufacture, and commercialize SPC-15.
Silo Pharma (NASDAQ: SILO) ha presentato una domanda di brevetto provvisorio presso l'USPTO per il suo principale asset SPC-15, mirato a trattamenti per disturbi psichiatrici indotti dallo stress, inclusa la PTSD. Il brevetto riguarda il targeting cronico e combinato dei recettori N-metil-D-aspartato (NMDAR) e dei recettori della serotonina di tipo IV (5-HT4R) per estendere gli effetti comportamentali contro il comportamento perseverativo indotto dallo stress e l'iponeofagia.
Questa presentazione arricchisce il portafoglio di proprietà intellettuale di Silo per la tecnologia SPC-15, che è stata originariamente concessa in licenza attraverso una collaborazione con Columbia University. L'accordo esclusivo conferisce a Silo diritti globali per sviluppare, produrre e commercializzare SPC-15.
Silo Pharma (NASDAQ: SILO) ha presentado una solicitud de patente provisional ante la USPTO para su principal activo SPC-15, dirigido a tratamientos para trastornos psiquiátricos inducidos por el estrés, incluida la PTSD. La patente cubre el objetivo crónico y combinatorio de los receptores de N-metil-D-aspartato (NMDAR) y los receptores de serotonina tipo IV (5-HT4R) para extender los efectos conductuales contra el comportamiento perseverante inducido por el estrés y la hiponeofagia.
Esta presentación mejora el portafolio de propiedad intelectual de Silo para la tecnología SPC-15, que fue licenciada originalmente a través de una colaboración con Columbia University. El acuerdo exclusivo otorga a Silo derechos globales para desarrollar, fabricar y comercializar SPC-15.
사일로 파마(SILO, NASDAQ: SILO)는 스트레스로 유발된 정신 장애 치료, 특히 PTSD를 대상으로 하는 주요 자산 SPC-15에 대한 임시 특허 신청서를 USPTO에 제출했습니다. 이 특허는 N-메틸-D-아스파르트산 수용체(NMDAR)와 세로토닌 IV형 수용체(5-HT4R)를 만성적으로 조합하여 표적화하여 스트레스로 유발된 지속적 행동과 저신규 행동에 대한 행동 효과를 연장하는 내용을 포함합니다.
이번 신청은 컬럼비아 대학교와의 협력을 통해 최초로 라이센스된 SPC-15 기술에 대한 사일로의 지적 재산 포트폴리오를 강화합니다. 독점 계약은 사일로에 SPC-15를 개발, 제조 및 상용화할 수 있는 글로벌 권리를 부여합니다.
Silo Pharma (NASDAQ: SILO) a déposé une demande de brevet provisoire auprès de l'USPTO pour son principal actif SPC-15, visant des traitements pour des troubles psychiatriques induits par le stress, y compris le PTSD. Le brevet couvre le ciblage chronique et combinatoire des récepteurs N-méthyl-D-aspartate (NMDAR) et des récepteurs de sérotonine de type IV (5-HT4R) pour étendre les effets comportementaux contre le comportement persistant induit par le stress et l'hyponeophagie.
Cette demande renforce le portefeuille de propriété intellectuelle de Silo pour la technologie SPC-15, qui a été initialement sous licence grâce à une collaboration avec l'Université de Columbia. L'accord exclusif confère à Silo des droits mondiaux pour développer, fabriquer et commercialiser SPC-15.
Silo Pharma (NASDAQ: SILO) hat einen vorläufigen Patentantrag bei der USPTO für sein Hauptprodukt SPC-15 eingereicht, das auf Behandlungen für stressbedingte psychiatrische Störungen, einschließlich PTSD, abzielt. Das Patent umfasst das chronische, kombinatorische Targeting von N-Methyl-D-Aspartat-Rezeptoren (NMDARs) und Serotonin Typ IV Rezeptoren (5-HT4Rs), um die Verhaltenswirkungen gegen stressbedingtes perseverierendes Verhalten und Hyponeophagie zu verlängern.
Diese Einreichung verbessert Silos geistiges Eigentum Portfolio für die SPC-15 Technologie, die ursprünglich in einer Zusammenarbeit mit der Columbia University lizenziert wurde. Die exklusive Vereinbarung gewährt Silo globale Rechte zur Entwicklung, Herstellung und Vermarktung von SPC-15.
- Filed new provisional patent application for PTSD treatment technology
- Holds exclusive global rights for SPC-15 development and commercialization through Columbia University agreement
- None.
Insights
The filing of a provisional patent application for SPC-15 marks a important step in Silo Pharma's IP strategy, particularly given the company's modest
The dual-targeting mechanism of SPC-15, focusing on both NMDARs and 5-HT4Rs, represents a novel approach in the PTSD treatment landscape. This combinatorial strategy could potentially offer improved efficacy compared to single-target treatments, addressing both the immediate stress response and longer-term behavioral modifications.
The exclusive global rights secured through the Columbia University collaboration significantly enhance Silo's competitive position. This partnership with a prestigious research institution not only provides technological validation but also offers potential access to additional research resources and expertise. However, investors should note that the path from provisional patent to commercialization typically requires substantial capital investment and successful clinical trials.
For a micro-cap biotech company like Silo, building a robust IP portfolio is essential for creating shareholder value and attracting potential strategic partnerships or licensing agreements. The provisional patent filing, while promising, represents an early stage in the drug development process, with significant clinical and regulatory milestones still ahead.
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo’s commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
The provisional patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia. This filing adds to Silo’s growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally.
“Silo Pharma’s intellectual property strategy continues to be a cornerstone of our growth,” said Eric Weisblum, CEO of Silo Pharma. “We believe this latest provisional patent application reinforces our strong IP protection for SPC-15 and further positions us to deliver innovative therapies for patients with PTSD and other stress-induced disorders.”
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the latest patent application filed by Silo Pharma (SILO) in January 2024?
What medical conditions does Silo Pharma's SPC-15 target?
What is the relationship between Silo Pharma and Columbia University regarding SPC-15?
What are the key components of Silo Pharma's new provisional patent for SPC-15?
